Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02755545 · ClinicalTrials.gov registry record · Phase 4

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

A Phase 4 study of Acne, sponsored by Galderma R&D.

Completed
Registry status
Phase 4
Development phase
127
Enrollment target
1
Study location

NCT02755545 is a Phase 4 study of Acne that has completed, run by Galderma R&D. The registered enrollment target is 127 participants, roughly in line with the 138-participant average among 26 other Acne trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02755545, a Phase 4 study of Acne, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 4
Development phase
127 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.

Conditions Studied

Interventions

  • DRUG Product A
  • DRUG Product B

Study Locations (1)

Texas

  • Stephens & Associates, Inc. Texas Research Center - Richardson

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2016-05-01
Est. Completion 2017-04-04
Phase Phase 4

Sponsor

Galderma R&D

158 total trials

What the Registry Record Tells You About NCT02755545

The ClinicalTrials.gov registry entry for NCT02755545 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 138-participant average among 26 other Acne trials with a reported enrollment target. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 2 interventions - of which Product A is the first listed.

NCT02755545 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02755545 about?

NCT02755545 is a clinical study titled "A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments". The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.

What is the current status of trial NCT02755545?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2016-05-01. Estimated completion is 2017-04-04.

What conditions does trial NCT02755545 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT02755545?

The interventions under investigation include: Product A (DRUG), Product B (DRUG).

Who is sponsoring clinical trial NCT02755545?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02755545 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.